Avacta announces appointment of new non-executive director

Drug devloper Avacta has announced the appointment of Dr Mark Goldberg as a non-executive director.
Dr Alastair Smith, CEO of  Wetherby-based Avacta, said: "I am very pleased to welcome Mark to the board."Dr Alastair Smith, CEO of  Wetherby-based Avacta, said: "I am very pleased to welcome Mark to the board."
Dr Alastair Smith, CEO of Wetherby-based Avacta, said: "I am very pleased to welcome Mark to the board."

Dr. Goldberg is a medical oncologist and haematologist on the faculty of Brigham & Women's Hospital and Harvard Medical School, a veteran biotech executive and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer.

He is the past-chair of the Eastern New England Area Board of the American Cancer Society and currently serves as a member of its national board of directors.

Hide Ad
Hide Ad

Dr. Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines.

He served on the board of directors of Audentes Therapeutics up to its acquisition by Astellas Pharma in 2020. Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2011-2014 and before that served in various management capacities of increasing responsibility at Genzyme Corporation from 1996-2011, most recently as senior vice president of clinical development.

Dr Alastair Smith, CEO of Wetherby-based Avacta, said: "I am very pleased to welcome Mark to the board. Mark is a vastly experienced biotech executive and oncologist and Avacta will benefit greatly from his future contributions to the strategy and vision for the therapeutic business."

---

Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

Hide Ad
Hide Ad

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson